(Q42643278)

4 November 2017

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions (English)

1 reference

4 November 2017

12

1 reference

4 November 2017

Günter Fingerle-Rowson

7

object named as

Günter Fingerle-Rowson

0 references

Michael Hallek

10

object named as

Michael Hallek

1 reference

4 November 2017

Ciara L Freeman

1

1 reference

4 November 2017

Franck Morschhauser

2

1 reference

4 November 2017

Laurie Sehn

3

1 reference

4 November 2017

Mark Dixon

4

1 reference

4 November 2017

Richard Houghton

5

1 reference

4 November 2017

Thierry Lamy

6

1 reference

4 November 2017

Günter Fingerle-Rowson

7

1 reference

4 November 2017

Elisabeth Wassner-Fritsch

8

1 reference

4 November 2017

John G Gribben

9

1 reference

4 November 2017

Gilles Salles

11

1 reference

4 November 2017

language of work or name

English

0 references

publication date

7 October 2015

1 reference

4 November 2017

1 reference

4 November 2017

126

1 reference

4 November 2017

24

1 reference

4 November 2017

2646-2649

1 reference

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

4 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Rituximab-induced thrombocytopenia: a cohort study.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Interleukin-6 in sepsis and capillary leakage syndrome

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Modulation of cytokine-induced production of IL-8 in vitro by interferons and glucocorticosteroids

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Tumor necrosis factor- induces adhesion molecule expression through the sphingosine kinase pathway

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4671111

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

1 December 2018

1 reference

12 December 2020

Ca2+ i Changes and Respiratory Burst in Human Neutrophils and Monocytes Induced by NAP-1/Interleukin-8, NAP-2, and gro /MGSA

1 reference

12 December 2020

Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis

1 reference

12 December 2020

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

1 reference

12 December 2020

10.1182/BLOOD-2015-09-670802

Identifiers

DOI

1 reference

4 November 2017

1 reference

4 November 2017

PubMed publication ID

26447188

1 reference